Back to News
Market Impact: 0.15
Abbott Reports First Commercial Use Of Volt Pulsed System In Canadian Atrial Fibrillation Care
Source: Nasdaq
Healthcare & BiotechProduct Launches
Abbott Laboratories announced that its Volt pulsed field ablation system was used for the first time in Canada at Montreal's McGill University Health Centre to treat atrial-fibrillation patients. The milestone expands real-world adoption of Abbott's cardiac-care technology, but no financial impact, sales outlook, or patient-volume data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ABT0.55
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can ChatGPT or Claude Replace a Research Platform?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance